MX2014012945A - Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). - Google Patents

Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Info

Publication number
MX2014012945A
MX2014012945A MX2014012945A MX2014012945A MX2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A
Authority
MX
Mexico
Prior art keywords
aminopyrimidine derivatives
lrrk2
pyrazole
modulators
lrrk2 modulators
Prior art date
Application number
MX2014012945A
Other languages
English (en)
Other versions
MX363118B (es
Inventor
Huifen Chen
Charles Baker-Glenn
Mark Chambers
Bryan K Chan
Anthony Estrada
Daniel Jon Burdick
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014012945A publication Critical patent/MX2014012945A/es
Publication of MX363118B publication Critical patent/MX363118B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de pirazol que son moduladores de LRRK2, con métodos para elaborar los compuestos, y con métodos para usar los compuestos para el tratamiento de enfermedades asociadas con el receptor LRRK2, tal como la enfermedad de Parkinson.
MX2014012945A 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). MX363118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642019P 2012-05-03 2012-05-03
PCT/EP2013/058939 WO2013164321A1 (en) 2012-05-03 2013-04-30 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (2)

Publication Number Publication Date
MX2014012945A true MX2014012945A (es) 2015-02-10
MX363118B MX363118B (es) 2019-03-11

Family

ID=48325675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012945A MX363118B (es) 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Country Status (11)

Country Link
US (1) US9212173B2 (es)
EP (1) EP2844652B1 (es)
JP (1) JP6218808B2 (es)
KR (1) KR102091894B1 (es)
CN (2) CN104271569B (es)
BR (1) BR112014026952B1 (es)
CA (1) CA2870049C (es)
HK (1) HK1200820A1 (es)
MX (1) MX363118B (es)
RU (1) RU2637947C2 (es)
WO (1) WO2013164321A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027117B1 (pt) * 2012-05-03 2022-09-06 Genentech, Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
KR20150027267A (ko) 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
WO2017156493A1 (en) * 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP3082819B1 (en) 2013-12-20 2020-06-17 Signal Pharmaceuticals, LLC Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
CN105980388B (zh) 2014-01-29 2018-01-16 葛兰素史密斯克莱知识产权发展有限公司 化合物
CR20160348A (es) 2014-01-29 2017-04-28 Glaxosmithline Intellectual Property Dev Ltd Compuestos
EP3172192A1 (en) * 2014-07-24 2017-05-31 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
MX2018003215A (es) 2015-09-14 2018-06-08 Pfizer Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
US10023579B2 (en) 2015-12-16 2018-07-17 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
CR20180592A (es) * 2016-06-16 2019-03-05 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
PE20210157A1 (es) 2017-11-21 2021-01-26 Denali Therapeutics Inc Polimorfos y formas solidas de un compuesto de pirimidinilamino-pirazol y metodos de produccion
JP7284172B2 (ja) * 2017-12-20 2023-05-30 デナリ セラピューティクス インコーポレイテッド ピリミジニル－４－アミノピラゾール化合物の調製方法
JP7364841B2 (ja) * 2018-02-14 2023-10-19 智彦 大和田 酸ハロゲン化物による化合物の製造方法
KR102501982B1 (ko) 2018-02-14 2023-02-20 오사카 유키가가쿠고교 가부시키가이샤 내열성과 용이 박리성의 경화수지막을 형성하는 경화성 수지 조성물 및 그의 제조 방법
US11130752B2 (en) 2018-09-25 2021-09-28 Cardurion Pharmaceuticals, Llc Aminopyrimidine compound
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
WO2020187292A1 (zh) * 2019-03-19 2020-09-24 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN116685325A (zh) 2020-10-20 2023-09-01 豪夫迈·罗氏有限公司 Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60128709T2 (de) * 2000-09-15 2007-12-27 Vertex Pharmaceuticals Inc., Cambridge Triazol-verbindungen als protein-kinase-inhibitoren
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
JP2012529522A (ja) * 2009-06-10 2012-11-22 アボット・ラボラトリーズ キナーゼ阻害剤としての２−（１ｈ−ピラゾール−４−イルアミノ）−ピリミジン
CA2797947C (en) * 2010-06-04 2019-07-09 Charles Baker-Glenn Aminopyrimidine derivatives as lrrk2 modulators
KR101837223B1 (ko) * 2010-09-01 2018-03-09 질레드 코네티컷 인코포레이티드 피리디논/피라지논, 그의 제조 방법 및 사용 방법
ES2653967T3 (es) * 2010-11-10 2018-02-09 Genentech, Inc. Derivados de pirazol aminopirimidina como moduladores de LRRK2
KR20140062079A (ko) * 2011-08-25 2014-05-22 에프. 호프만-라 로슈 아게 세린/트레오닌 pak1 억제제
MX2014005282A (es) * 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de 8-fluoroftalazin-1 (2h) -ona.
JP6068515B2 (ja) * 2012-03-01 2017-01-25 アレイ バイオファーマ、インコーポレイテッド セリン／トレオニンキナーゼ阻害剤
EP2900657B1 (en) * 2012-09-26 2020-03-11 F.Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MY182082A (en) * 2013-05-01 2021-01-18 Hoffmann La Roche Biheteroaryl compounds and uses thereof

Also Published As

Publication number Publication date
BR112014026952B1 (pt) 2022-03-15
KR20150016532A (ko) 2015-02-12
CA2870049A1 (en) 2013-11-07
RU2637947C2 (ru) 2017-12-08
US20150051238A1 (en) 2015-02-19
KR102091894B1 (ko) 2020-03-20
JP2015515966A (ja) 2015-06-04
BR112014026952A2 (pt) 2017-06-27
HK1200820A1 (zh) 2015-08-14
EP2844652B1 (en) 2019-03-13
US9212173B2 (en) 2015-12-15
CN104271569A (zh) 2015-01-07
MX363118B (es) 2019-03-11
CA2870049C (en) 2020-12-29
EP2844652A1 (en) 2015-03-11
RU2014147381A (ru) 2016-06-27
WO2013164321A1 (en) 2013-11-07
JP6218808B2 (ja) 2017-10-25
CN104271569B (zh) 2016-08-24
BR112014026952A8 (pt) 2021-06-15
CN106220615A (zh) 2016-12-14

Similar Documents

Publication Publication Date Title
MX2014012945A (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
NZ737399A (en) Ccr2 modulators
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
SG194718A1 (en) Novel compounds as modulators of protein kinases
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
MX2015009773A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2015000129A (es) Derivados de pirimidin pirazolilo.
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
PL2785711T3 (pl) Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona
MX2015009778A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX361349B (es) Moduladores del receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dérmicas.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).